{
    "organizations": [],
    "uuid": "ecbe59cca411dd298c95f036ffca82d7eac42d90",
    "author": "",
    "url": "https://www.reuters.com/article/brief-apricus-biosciences-receives-compl/brief-apricus-biosciences-receives-complete-response-letter-from-fda-for-vitaros-idUSASB0C65Q",
    "ord_in_thread": 0,
    "title": "BRIEF-Apricus Biosciences Receives Complete Response Letter From FDA For Vitaros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 16, 2018 / 12:40 PM / in 11 minutes BRIEF-Apricus Biosciences Receives Complete Response Letter From FDA For Vitaros Reuters Staff Feb 16 (Reuters) - Apricus Biosciences Inc: * APRICUS BIOSCIENCES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR VITAROS * APRICUS BIOSCIENCES INC - CRL INDICATES THAT FDA CANNOT APPROVE NDA FOR VITAROS IN ITS PRESENT FORM * APRICUS BIOSCIENCES INC - CRL IDENTIFIES DEFICIENCIES RELATED TO CHEMISTRY, MANUFACTURING AND CONTROL FOR VITAROS * APRICUS BIOSCIENCES - CRL ALSO IDENTIFIES CERTAIN SAFETY CONCERNS SPECIFIC TO 2.5% CONCENTRATION OF DDAIP.HCL IN CURRENT FORMULATION FOR VITAROS * APRICUS BIOSCIENCES INC - GOAL OF PROVIDING MARKET AN UPDATE ON CRL ASSESSMENT IN EARLY MARCH OF THIS YEAR Source text for Eikon: Further company coverage:",
    "published": "2018-02-16T14:39:00.000+02:00",
    "crawled": "2018-02-16T14:58:30.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "bioscience",
        "receives",
        "complete",
        "response",
        "letter",
        "fda",
        "vitaros",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "apricus",
        "bioscience",
        "inc",
        "apricus",
        "bioscience",
        "receives",
        "complete",
        "response",
        "letter",
        "fda",
        "vitaros",
        "apricus",
        "bioscience",
        "inc",
        "crl",
        "indicates",
        "fda",
        "approve",
        "nda",
        "vitaros",
        "present",
        "form",
        "apricus",
        "bioscience",
        "inc",
        "crl",
        "identifies",
        "deficiency",
        "related",
        "chemistry",
        "manufacturing",
        "control",
        "vitaros",
        "apricus",
        "bioscience",
        "crl",
        "also",
        "identifies",
        "certain",
        "safety",
        "concern",
        "specific",
        "concentration",
        "current",
        "formulation",
        "vitaros",
        "apricus",
        "bioscience",
        "inc",
        "goal",
        "providing",
        "market",
        "update",
        "crl",
        "assessment",
        "early",
        "march",
        "year",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}